Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681015 · ClinicalTrials.gov registry record
Wearable Assessments in the Clinic and Home in PD
A clinical trial of Parkinson Disease, sponsored by University of Rochester.
- Completed
- Registry status
- 132
- Enrollment target
- 17
- Study locations
NCT03681015: Completed study of Parkinson Disease, sponsored by University of Rochester.
NCT03681015 is a study of Parkinson Disease that has completed, run by University of Rochester. The registered enrollment target is 132 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03681015, a study of Parkinson Disease, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 132 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to evaluate disease progression in persons with early Parkinson disease, as assessed by digital and electronic sensor data collection to be correlated with typical clinical assessments.
Primary Outcome
Features will be extracted from continuous accelerometer and gyroscope signals, obtained via a set of body-worn inertial sensors, during performance of the MDS-UPDRS part 3, and the change and variability of these features will be assessed.
Conditions Studied
Study Locations (17)
New York
- Northwell Health - Great Neck
- NYU Langone Health - New York
- University of Rochester - Rochester
Ohio
- University of Cincinnati - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
Virginia
- Virginia Commonwealth University - Richmond
- Sentara Clinical Research - Virginia Beach
Arizona
- Banner Sun Research Institute - Sun City
California
- University of California San Francisco - San Francisco
Colorado
- University of Colorado Denver - Aurora
Florida
- University of South Florida - Tampa
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2022-03-30 |
What the finished NCT03681015 record still lists
NCT03681015 is an observational study that tracks outcomes without assigning an intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03681015 lists 17 locations in 13 states (New York, Ohio, Virginia).
Frequently Asked Questions
What is clinical trial NCT03681015 about?
NCT03681015 is a clinical study titled "Wearable Assessments in the Clinic and Home in PD". The purpose of this study is to evaluate disease progression in persons with early Parkinson disease, as assessed by digital and electronic sensor data collection to be correlated with typical clinical assessments.
What is the current status of trial NCT03681015?
This trial is currently completed. The enrollment target is 132 participants. The study started on 2019-04-24. Estimated completion is 2022-03-30.
What conditions does trial NCT03681015 study?
This clinical trial studies the following conditions: Parkinson Disease.
Who is sponsoring clinical trial NCT03681015?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03681015 being conducted?
This trial has 17 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03681015's enrollment target sits among peer trials
132 62nd of 297 higher than 235 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI